Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostictreatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.
Resources on Agnostics:
The Evolving Landscape of Tissue-Agnostic Therapies in Precision Oncology
TAPUR (Targeted Agent & Profiling Study): The TAPUR Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)- approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.